0RG8.L - Sartorius Stedim Biotech S.A.
LSE - LSE Delayed price. Currency in EUR
At close: 06:45PM BST
Stock chart is not supported by your current browser
| Previous close | 339.65 |
| Open | 338.90 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 338.90 - 354.90 |
| 52-week range | 338.90 - 354.90 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireNine-month results 2022 of Sartorius Stedim Biotech
Sartorius Stedim Biotech, a leading partner of the biopharma industry, closed the first nine months of 2022 with double-digit sales revenue and earnings growth and specified its outlook for the current fiscal year.
PR NewswireSartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions
Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapi